{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T04:32:15Z","timestamp":1770179535427,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Today"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00595-025-03161-4","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:12:18Z","timestamp":1763532738000},"page":"107-114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of pimitespib in gastrointestinal tumors"],"prefix":"10.1007","volume":"56","author":[{"given":"Kunihiko","family":"Kawai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4645-2056","authenticated-orcid":false,"given":"Tsuyoshi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taroh","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaomi","family":"Hagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kota","family":"Momose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Makino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyokazu","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"3161_CR1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1126\/science.279.5350.577","volume":"279","author":"S Hirota","year":"1998","unstructured":"Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577\u201380.","journal-title":"Science"},{"key":"3161_CR2","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1126\/science.1079666","volume":"299","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708\u201310.","journal-title":"Science"},{"key":"3161_CR3","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","volume":"21","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342\u20139.","journal-title":"J Clin Oncol"},{"key":"3161_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of Imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472\u201380.","journal-title":"N Engl J Med"},{"key":"3161_CR5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","volume":"364","author":"J Verweij","year":"2004","unstructured":"Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127\u201334.","journal-title":"Lancet"},{"issue":"Suppl 2","key":"3161_CR6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2010.0116","volume":"8","author":"GD Demetri","year":"2010","unstructured":"Demetri GD, von Mehren M, Antonescu CR, et al. NCCN task force report: update on the management of patients with Gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8(Suppl 2):S1\u201341. quiz S42.","journal-title":"J Natl Compr Canc Netw"},{"key":"3161_CR7","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1200\/JCO.2004.05.140","volume":"22","author":"CL Corless","year":"2004","unstructured":"Corless CL, Fletcher JA, Heinrich MC. Biology of Gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813\u201325.","journal-title":"J Clin Oncol"},{"key":"3161_CR8","doi-asserted-by":"publisher","first-page":"7510","DOI":"10.1158\/1078-0432.CCR-09-0190","volume":"15","author":"AW Gramza","year":"2009","unstructured":"Gramza AW, Corless CL, Heinrich MC. Resistance to tyrosine kinase inhibitors in Gastrointestinal stromal tumors. Clin Cancer Res. 2009;15:7510\u20138.","journal-title":"Clin Cancer Res"},{"key":"3161_CR9","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","volume":"26","author":"MC Heinrich","year":"2008","unstructured":"Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of Sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26:5352\u20139.","journal-title":"J Clin Oncol"},{"key":"3161_CR10","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","volume":"364","author":"J Verweij","year":"2004","unstructured":"Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127\u201334.","journal-title":"Lancet"},{"key":"3161_CR11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced Gastrointestinal stromal tumours after failure of Imatinib and sunitinib(GRID): an international, multicentre, prospective, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295\u2013302.","journal-title":"Lancet"},{"key":"3161_CR12","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of Sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329\u201338.","journal-title":"Lancet"},{"key":"3161_CR13","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1016\/S1470-2045(13)70169-4","volume":"14","author":"R Garcia-Carbonero","year":"2013","unstructured":"Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 2013;14:e358-69.","journal-title":"Lancet Oncol"},{"key":"3161_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1535-6108(03)00029-1","volume":"3","author":"JS Isaacs","year":"2003","unstructured":"Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell. 2003;3:213\u20137.","journal-title":"Cancer Cell"},{"key":"3161_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1196\/annals.1391.012","volume":"1113","author":"P Workman","year":"2007","unstructured":"Workman P, Burrows F, Neckers L, et al. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci. 2007;1113:202\u201316.","journal-title":"Ann N Y Acad Sci"},{"key":"3161_CR16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1042\/BJ20071640","volume":"410","author":"LH Pearl","year":"2008","unstructured":"Pearl LH, Prodromou C, Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J. 2008;410:439\u201353.","journal-title":"Biochem J"},{"key":"3161_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/1078-0432.CCR-08-0132","volume":"15","author":"U Banerji","year":"2009","unstructured":"Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res. 2009;15:9\u201314.","journal-title":"Clin Cancer Res"},{"key":"3161_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.molmed.2004.04.006","volume":"10","author":"A Kamal","year":"2004","unstructured":"Kamal A, Boehm MF, Burrows FJ. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med. 2004;10:283\u201390.","journal-title":"Trends Mol Med"},{"key":"3161_CR19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0093-7754(03)00346-4","volume":"30","author":"DB Solit","year":"2003","unstructured":"Solit DB, Scher HI, Rosen N. Hsp90 as a therapeutic target in prostate cancer. Semin Oncol. 2003;30:709\u201316.","journal-title":"Semin Oncol"},{"key":"3161_CR20","first-page":"2228","volume":"7","author":"PN M\u00fcnster","year":"2001","unstructured":"M\u00fcnster PN, Basso A, Solit D, et al. Modulation of Hsp90 function by ansamycins sensitises breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res. 2001;7:2228\u201336.","journal-title":"Clin Cancer Res"},{"key":"3161_CR21","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/sj.leu.2402257","volume":"15","author":"MV Blagosklonny","year":"2001","unstructured":"Blagosklonny MV, Fojo T, Bhalla KN, et al. The Hsp90 inhibitor geldanamycin selectively sensitises Bcr-Ablexpressing leukemia cells to cytotoxic chemotherapy. Leukemia. 2001;15:1537\u201343.","journal-title":"Leukemia"},{"key":"3161_CR22","first-page":"2945","volume":"61","author":"PN M\u00fcnster","year":"2001","unstructured":"M\u00fcnster PN, Srethapakdi M, Moasser MM, et al. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res. 2001;61:2945\u201352.","journal-title":"Cancer Res"},{"key":"3161_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1021\/jm9004708","volume":"53","author":"MA Biamonte","year":"2010","unstructured":"Biamonte MA, Van de Water R, Arndt JW, et al. Heat shock protein 90: inhibitors in clinical trials. J Med Chem. 2010;53:3\u201317.","journal-title":"J Med Chem"},{"key":"3161_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.humpath.2007.03.001","volume":"38","author":"JL Hornick","year":"2007","unstructured":"Hornick JL, Fletcher CD. The role of KIT in the management of patients with gastrointestinal stromal tumors. Hum Pathol. 2007;38:679\u201387.","journal-title":"Hum Pathol"},{"key":"3161_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0163-7258(98)00013-8","volume":"79","author":"P Csermely","year":"1998","unstructured":"Csermely P, Schnaider T, Soti C, et al. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A Compre Hensive review. Pharmacol Ther. 1998;79:129\u201368.","journal-title":"Pharmacol Ther"},{"key":"3161_CR26","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.2174\/156802606777812068","volume":"6","author":"DB Solit","year":"2006","unstructured":"Solit DB, Rosen N. Hsp90: a novel target for cancer therapy. Curr Top Med Chem. 2006;6:1205\u201314.","journal-title":"Curr Top Med Chem"},{"key":"3161_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1158\/1535-7163.MCT-14-0219","volume":"14","author":"S Ohkubo","year":"2015","unstructured":"Ohkubo S, Kodama Y, Muraoka H, et al. TAS-116, a highly selective inhibitor of heat shock protein 90a and b, demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models. Mol Cancer Ther. 2015;14:14\u201322.","journal-title":"Mol Cancer Ther"},{"key":"3161_CR28","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1021\/acs.jmedchem.0c01715","volume":"64","author":"C Yoshimura","year":"2021","unstructured":"Yoshimura C, Nagatoishi S, Kuroda D, et al. Thermodynamic dissection of potency and selectivity of cytosolic HSP90 inhibitors. J Med Chem. 2021;64:2669\u201377.","journal-title":"J Med Chem"},{"key":"3161_CR29","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.annonc.2022.05.518","volume":"33","author":"Y Kurokawa","year":"2022","unstructured":"Kurokawa Y, Honma Y, Sawaki A, et al. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2022;33:959\u201367.","journal-title":"Ann Oncol"},{"key":"3161_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejca.2019.08.009","volume":"121","author":"T Doi","year":"2019","unstructured":"Doi T, Kurokawa Y, Sawaki A, et al. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial. Eur J Cancer. 2019;121:29\u201339.","journal-title":"Eur J Cancer"},{"key":"3161_CR31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1158\/1535-7163.MCT-18-0831","volume":"18","author":"A Shimomura","year":"2019","unstructured":"Shimomura A, Yamamoto N, Kondo S, et al. First-in-Human phase I study of an oral HSP90 Inhibitor, TAS-116, advanced solid tumors. Mol Cancer Ther. 2019;18:531\u201340.","journal-title":"Mol Cancer Ther"},{"key":"3161_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2131\/jts.39.59","volume":"39","author":"C Kanamaru","year":"2014","unstructured":"Kanamaru C, Yamada Y, Hayashi S, et al. Retinal toxicity induced by small-molecule Hsp90 inhibitors in beagle dogs. J Toxicol Sci. 2014;39:59\u201369.","journal-title":"J Toxicol Sci"},{"key":"3161_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.taap.2016.08.025","volume":"309","author":"D Roman","year":"2016","unstructured":"Roman D, VerHoeve J, Schadt H, et al. Ocular toxicity of AUY922 in pigmented and albino rats. Toxicol Appl Pharmacol. 2016;309:55\u201362.","journal-title":"Toxicol Appl Pharmacol"},{"key":"3161_CR34","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.taap.2013.09.018","volume":"273","author":"D Zhou","year":"2013","unstructured":"Zhou D, Liu Y, Ye J, et al. A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors. Toxicol Appl Pharmacol. 2013;273:401\u20139.","journal-title":"Toxicol Appl Pharmacol"},{"key":"3161_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-3-319-17121-0_22","volume":"854","author":"M Aguil\u00e0","year":"2016","unstructured":"Aguil\u00e0 M, Cheetham ME. Hsp90 as a potential therapeutic target in retinal disease. Adv Exp Med Biol. 2016;854:161\u20137. https:\/\/doi.org\/10.1007\/978-3-319-17121-0_22.","journal-title":"Adv Exp Med Biol"},{"issue":"13","key":"3161_CR36","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/cncr.29339","volume":"121","author":"R Seggewiss-Bernhardt","year":"2015","unstructured":"Seggewiss-Bernhardt R, Bargou RC, Goh YT. Phase 1\/1<scp>B<\/scp> trial of the heat shock protein 90 inhibitor <scp>NVP<\/scp>\u2010<scp>AUY<\/scp>922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer. 2015;121(13):2185\u201392. https:\/\/doi.org\/10.1002\/cncr.29339.","journal-title":"Cancer"},{"key":"3161_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/342986","volume":"2014","author":"A Sawaki","year":"2014","unstructured":"Sawaki A, Kanda T, Komatsu Y, et al. Impact of rechallenge with Imatinib in patients with advanced gastrointestinal stromal tumor after failure of Imatinib and Sunitinib. Gastroenterol Res Pract. 2014;2014:342986.","journal-title":"Gastroenterol Res Pract"},{"key":"3161_CR38","doi-asserted-by":"publisher","DOI":"10.1177\/1758835918794623","volume":"10","author":"B Vincenzi","year":"2018","unstructured":"Vincenzi B, Nannini M, Badalamenti G, et al. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. Ther Adv Med Oncol. 2018;10:1758835918794623. https:\/\/doi.org\/10.1177\/1758835918794623.","journal-title":"Ther Adv Med Oncol"},{"key":"3161_CR39","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1245\/s10434-011-2120-6","volume":"19","author":"A Italiano","year":"2012","unstructured":"Italiano A, Cioffi A, Coco P, et al. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. Ann Surg Oncol. 2012;19:1551\u20139.","journal-title":"Ann Surg Oncol"},{"key":"3161_CR40","doi-asserted-by":"crossref","unstructured":"Hirano H, Naito Y, Sundar R et al. (2024) CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor. J Clin Oncol 42 supple:TPS97\u2013TPS97.","DOI":"10.1200\/JCO.2024.42.23_suppl.TPS97"},{"key":"3161_CR41","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/ijc.34461","volume":"152","author":"R Teranishi","year":"2023","unstructured":"Teranishi R, Takahashi T, Obata Y, et al. Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors. Int J Cancer. 2023;152:2580\u201393.","journal-title":"Int J Cancer"}],"container-title":["Surgery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-025-03161-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00595-025-03161-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-025-03161-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T06:57:21Z","timestamp":1770015441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00595-025-03161-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3161"],"URL":"https:\/\/doi.org\/10.1007\/s00595-025-03161-4","relation":{},"ISSN":["0941-1291","1436-2813"],"issn-type":[{"value":"0941-1291","type":"print"},{"value":"1436-2813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"30 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Human Ethics Review Committee of Osaka University Graduate School of Medicine approved the protocol for this retrospective study (Approval No. 22316). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and the Helsinki Declaration of 1964 and later versions. Informed consent for this study, or equivalent, was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from all individuals whose data appeared in the paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Yukinori Kurokawa received honoraria and research funding from Taiho Pharmaceutical.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}